These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26436906)

  • 21. Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides.
    Mirzadeh S
    J Med Imaging Radiat Sci; 2019 Dec; 50(4 Suppl 1):S21-S25. PubMed ID: 31420270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation.
    Zalutsky MR
    J Nucl Med; 2006 Aug; 47(8):1238-40. PubMed ID: 16882999
    [No Abstract]   [Full Text] [Related]  

  • 23. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
    Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
    Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis.
    Macklis RM; Lin JY; Beresford B; Atcher RW; Hines JJ; Humm JL
    Radiat Res; 1992 May; 130(2):220-6. PubMed ID: 1574578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeted radiation for melanoma: alpha therapy prepares for a beta test.
    Contessa JN; Roberson PL
    Cancer Biol Ther; 2006 Jan; 5(1):118-9. PubMed ID: 16491043
    [No Abstract]   [Full Text] [Related]  

  • 27. Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms.
    Cooks T; Arazi L; Schmidt M; Marshak G; Kelson I; Keisari Y
    Int J Cancer; 2008 Apr; 122(7):1657-64. PubMed ID: 18059026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing a dedicated comprehensive α-radionuclide therapy program: should this be the vision of the atomic energy programs in the next decade?
    Basu S; Banerjee S
    Nucl Med Commun; 2017 Feb; 38(2):103-105. PubMed ID: 27906780
    [No Abstract]   [Full Text] [Related]  

  • 29. Optimal therapeutic strategies for radioimmunotherapy.
    O'Donoghue JA
    Recent Results Cancer Res; 1996; 141():77-99. PubMed ID: 8722421
    [No Abstract]   [Full Text] [Related]  

  • 30. Quantitative imaging of 223Ra-chloride (Alpharadin) for targeted alpha-emitting radionuclide therapy of bone metastases.
    Hindorf C; Chittenden S; Aksnes AK; Parker C; Flux GD
    Nucl Med Commun; 2012 Jul; 33(7):726-32. PubMed ID: 22513884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
    Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha particles as radiopharmaceuticals in the treatment of bone metastases: mechanism of action of radium-223 chloride (Alpharadin) and radiation protection.
    Cheetham PJ; Petrylak DP
    Oncology (Williston Park); 2012 Apr; 26(4):330-7, 341. PubMed ID: 22655525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia.
    Huneke RB; Pippin CG; Squire RA; Brechbiel MW; Gansow OA; Strand M
    Cancer Res; 1992 Oct; 52(20):5818-20. PubMed ID: 1394209
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The treatment of solid tumors by alpha emitters released from (224)Ra-loaded sources-internal dosimetry analysis.
    Arazi L; Cooks T; Schmidt M; Keisari Y; Kelson I
    Phys Med Biol; 2010 Feb; 55(4):1203-18. PubMed ID: 20124656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alpha- and beta-emitting radiolanthanides in targeted cancer therapy: the potential role of terbium-149.
    Allen BJ; Blagojevic N
    Nucl Med Commun; 1996 Jan; 17(1):40-7. PubMed ID: 8692472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha-particles for targeted therapy.
    Sgouros G
    Adv Drug Deliv Rev; 2008 Sep; 60(12):1402-6. PubMed ID: 18541332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted cancer treatment.
    Goldenberg DM
    Immunol Today; 1989 Sep; 10(9):286-8. PubMed ID: 2590380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microdosimetric analysis of alpha-particle-emitting targeted radiotherapeutics using histological images.
    Akabani G; Kennel SJ; Zalutsky MR
    J Nucl Med; 2003 May; 44(5):792-805. PubMed ID: 12732682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
    Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radioimmunoconjugates in acute leukemia treatment: the future is radiant.
    Kotzerke J; Bunjes D; Scheinberg DA
    Bone Marrow Transplant; 2005 Dec; 36(12):1021-6. PubMed ID: 16247432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.